Trial Profile
Maintenance Therapy With Azacitidine and Valproic Acid After Allogeneic Stem Cell Transplant in Patients With High-Risk Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)(Version 1_06 Jan 2012)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Valproic acid
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 23 Apr 2021 Planned End Date changed from 1 Jan 2021 to 1 Jan 2022.
- 23 Apr 2021 Planned primary completion date changed from 1 Jan 2020 to 1 Jan 2022.
- 26 Feb 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2020.